BR112021000050A2 - Inibidores de triazol glicolato oxidase - Google Patents

Inibidores de triazol glicolato oxidase Download PDF

Info

Publication number
BR112021000050A2
BR112021000050A2 BR112021000050-0A BR112021000050A BR112021000050A2 BR 112021000050 A2 BR112021000050 A2 BR 112021000050A2 BR 112021000050 A BR112021000050 A BR 112021000050A BR 112021000050 A2 BR112021000050 A2 BR 112021000050A2
Authority
BR
Brazil
Prior art keywords
group
alkyl
pharmaceutically acceptable
acceptable salt
triazole
Prior art date
Application number
BR112021000050-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans Maag
Miguel Xavier FERNANDES
Robert Zamboni
Elham Akbariromani
Marc-Andre BEAULIEU
Yves LeBlanc
Pallavi Thakur
Original Assignee
Orfan Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orfan Biotech Inc. filed Critical Orfan Biotech Inc.
Publication of BR112021000050A2 publication Critical patent/BR112021000050A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112021000050-0A 2018-07-06 2019-07-05 Inibidores de triazol glicolato oxidase BR112021000050A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US62/694,918 2018-07-06
US201962827573P 2019-04-01 2019-04-01
US62/827,573 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (1)

Publication Number Publication Date
BR112021000050A2 true BR112021000050A2 (pt) 2021-04-06

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000050-0A BR112021000050A2 (pt) 2018-07-06 2019-07-05 Inibidores de triazol glicolato oxidase

Country Status (14)

Country Link
US (2) US11401246B2 (https=)
EP (1) EP3817816A1 (https=)
JP (1) JP7348705B2 (https=)
KR (1) KR102865323B1 (https=)
CN (1) CN112399873B (https=)
AU (1) AU2019297523B2 (https=)
BR (1) BR112021000050A2 (https=)
CO (1) CO2021001277A2 (https=)
IL (1) IL279952B2 (https=)
MX (1) MX2021000051A (https=)
PE (1) PE20210859A1 (https=)
SA (1) SA521420951B1 (https=)
SG (1) SG11202012930RA (https=)
WO (1) WO2020010309A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012930RA (en) 2018-07-06 2021-01-28 Orfan Biotech Inc Triazole glycolate oxidase inhibitors
AU2020376792B2 (en) 2019-11-01 2025-10-02 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
ES3049309T3 (en) * 2020-01-08 2025-12-16 Cantero Therapeutics Inc Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
CA3234440A1 (en) * 2021-10-11 2023-04-20 Jonathan C. Fox 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
CN120225507A (zh) * 2022-11-25 2025-06-27 海思科医药集团股份有限公司 一种三唑衍生物及其在医药上的应用
WO2024212137A1 (en) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
US20140213538A1 (en) 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
WO2016148193A1 (ja) 2015-03-19 2016-09-22 興人ライフサイエンス株式会社 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物
EP3386949A4 (en) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2019133813A1 (en) 2017-12-29 2019-07-04 Orfan Biotech Inc. Glycolate oxidase inhibitors and use thereof
WO2019165159A1 (en) 2018-02-23 2019-08-29 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
SG11202012930RA (en) 2018-07-06 2021-01-28 Orfan Biotech Inc Triazole glycolate oxidase inhibitors
WO2020257487A1 (en) 2019-06-19 2020-12-24 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease

Also Published As

Publication number Publication date
SG11202012930RA (en) 2021-01-28
CA3104529A1 (en) 2020-01-09
JP7348705B2 (ja) 2023-09-21
MX2021000051A (es) 2021-03-25
CO2021001277A2 (es) 2021-04-30
EP3817816A1 (en) 2021-05-12
KR20210041564A (ko) 2021-04-15
US20230143491A1 (en) 2023-05-11
CN112399873A (zh) 2021-02-23
CN112399873B (zh) 2024-10-25
IL279952B1 (en) 2024-07-01
SA521420951B1 (ar) 2024-03-24
AU2019297523B2 (en) 2025-04-17
WO2020010309A9 (en) 2020-01-30
IL279952B2 (en) 2024-11-01
US11401246B2 (en) 2022-08-02
WO2020010309A1 (en) 2020-01-09
IL279952A (en) 2021-03-01
JP2021530560A (ja) 2021-11-11
AU2019297523A1 (en) 2021-02-25
KR102865323B1 (ko) 2025-09-26
PE20210859A1 (es) 2021-05-18
US20210403439A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
BR112021000050A2 (pt) Inibidores de triazol glicolato oxidase
CN104822661B (zh) 5‑氨基四氢喹啉‑2‑羧酸及其用途
WO2023062575A1 (en) Cyclic vinyl sulfone compounds as wrn inhibitors
JP5330989B2 (ja) (アザ)インドール誘導体及びその医薬用途
JP5624894B2 (ja) アゼチジン誘導体
CN116323598B (zh) 三嗪二酮类衍生物、其制备方法及其在医药上的应用
WO2007037534A1 (ja) 2-へテロアリール置換インドール誘導体
US20210171503A1 (en) Glycolate oxidase inhibitors and use thereof
ES3049309T3 (en) Processes for preparing triazole glycolate oxidase inhibitors
JP5563985B2 (ja) フェニルイソニコチン酸誘導体及びその医薬用途
CA3104529C (en) Triazole glycolate oxidase inhibitors
EP4578855A1 (en) Prolyl hydroxylase inhibitor and use thereof
JP2022500423A (ja) エストロゲン受容体陽性乳癌の治療のための併用療法
CN115052478A (zh) Trpv4受体配体
JP2004520433A (ja) 処置方法
WO2024212137A1 (en) Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound
KR20250096635A (ko) Tyk2 억제제 및 이의 용도
HK1180327A1 (en) Thioacetate compounds, compositions and methods of use
HK1180327B (en) Thioacetate compounds, compositions and methods of use
JPS61221163A (ja) アントラニル酸誘導体

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CANTERO THERAPEUTICS, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]